PPBP and nonpapillary renal cell carcinoma: In another study, a prospective phase II multicenter trials in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials), Dufies et al. showed that a cytokine involved in inflammation and angiogenesis, CXCL7, may be considered as a predictive marker of sunitinib efficacy for ccRCC patients.